Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | US

Overview

Corporate Details

ISIN(s):
US3968791083
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Denali Therapeutics Inc. Logo
Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.
United States of America DNLI
Dermapharm Holding SE Logo
Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.
Germany DMP
Dermata Therapeutics, Inc. Logo
Develops OTC skin treatments using a unique delivery technology from freshwater sponges.
United States of America DRMA
Design Therapeutics, Inc. Logo
Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.
United States of America DSGN
Deutsche Biotech Innovativ AG Logo
Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.
Germany DBI
DEVA HOLDİNG A.Ş. Logo
Global manufacturer of human/veterinary pharmaceuticals, APIs, and medical ampoules.
Spain DEVA
Devyser Diagnostics Logo
Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.
Sweden DVYSR
DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America DMAC
Diamyd Medical AB (publ) Logo
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden DMYD
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America DNTH

Talk to a Data Expert

Have a question? We'll get back to you promptly.